Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters

Y. Hagino\textsuperscript{a}, Y. Takamatsu\textsuperscript{a}, H. Yamamoto\textsuperscript{a}, T. Iwamura\textsuperscript{b}, D. L. Murphy\textsuperscript{c}, G. R. Uhl\textsuperscript{d}, I. Sora\textsuperscript{e} and K. Ikeda\textsuperscript{a,*}

\textsuperscript{a}Division of Psychobiology, Tokyo Institute of Psychiatry, Tokyo 156-8585, Japan; \textsuperscript{b}Faculty of Pharmaceutical Sciences, Matsuyama University, Matsuyama 790-8578, Japan; \textsuperscript{c}Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland, USA; \textsuperscript{d}Molecular Neurobiology Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA; \textsuperscript{e}Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan

Abstract: 3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The present study investigated the effects of MDMA on extracellular dopamine (DA\textsubscript{ex}) and serotonin (5-HT\textsubscript{ex}) levels in the striatum and prefrontal cortex (PFC) using \textit{in vivo} microdialysis techniques in mice lacking DA transporters (DAT) and/or 5-HT transporters (SERT). Subcutaneous injection of MDMA (3, 10 mg/kg) significantly increased striatal DA\textsubscript{ex} in wild-type mice, SERT knockout mice, and DAT knockout mice, but not in DAT/SERT double-knockout mice. The MDMA-induced increase in striatal DA\textsubscript{ex} in SERT knockout mice was significantly less than in wildtype mice. In the PFC, MDMA dose-dependently increased DA\textsubscript{ex} levels in wildtype, DAT knockout, SERT knockout and DAT/SERT double-knockout mice to a similar extent. In contrast, MDMA markedly increased 5-HT\textsubscript{ex} in wildtype and DAT knockout mice and slightly increased 5-HT\textsubscript{ex} in SERT-KO and DAT/SERT double-knockout mice. The results confirm that MDMA acts at both DAT and SERT and increases DA\textsubscript{ex} and 5-HT\textsubscript{ex}.

Keywords: MDMA, serotonin transporter, dopamine transporter, knockout, microdialysis.

INTRODUCTION

3,4-Methylendioxymethamphetamine (MDMA, street name: ecstasy) exhibits both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical hallucinogens or psychostimulants. Under \textit{in vitro} conditions, MDMA has been shown to increase the release of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) from brain slices and prevent the reuptake of DA, 5-HT, and NE into brain synaptosomes [1-4]. MDMA binds with higher affinity to the 5-HT transporter (SERT) than to the DA transporter (DAT) [5, 6] and produces a greater release of 5-HT than DA [7-9].

\textit{In vivo} microdialysis studies have revealed that systemic injection of MDMA increases extracellular levels of DA and 5-HT in the striatum and prefrontal cortex (PFC) [7, 10-13]. MDMA induces DA release, at least in the striatum, through several mechanisms. For example, the release of DA elicited by MDMA is hypothesized to involve both transporter- [14, 15] and impulse-dependent processes [8]. Additionally, the increased 5-HT function resulting from MDMA-induced 5-HT\textsubscript{ex} release has been suggested to stimulate 5-HT\textsubscript{2} receptors, thereby further enhancing DA release [11, 16, 17].

Monoamine transporter knockout (KO) mice provide useful \textit{in vivo} models to analyze the effects of psychoactive drugs. In SERT-KO mice, Begels \textit{et al.} (1998) reported a lack of locomotor-stimulating effects of MDMA [18]. MDMA self-administration is also absent in SERT-KO mice [13]. Moreover, the ability of MDMA administration to induce \textgamma-amino butyric acid transporter 1 expression in the frontal cortex and midbrain was reduced in SERT-KO mice [19]. In contrast, DAT-KO mice are hyperactive [20, 21] and display perseverative locomotor patterns [22]. MDMA decreases hyperactivity and potentiates the perseverative pattern of locomotor activity in DAT-KO mice [23]. However, the mechanisms underlying these MDMA effects have not been sufficiently elucidated.

To clarify the action of MDMA on the DAT or SERT in the striatum and PFC, we investigated the effects of MDMA on extracellular levels of DA (DA\textsubscript{ex}) and 5-HT (5-HT\textsubscript{ex}) using \textit{in vivo} microdialysis in mice lacking the DAT and/or SERT.

METHODS

Animals

Wildtype and DAT-KO mouse littermates from crosses of heterozygous/heterozygous DAT-KO mice on a 129/C57 mixed genetic background served as subjects. SERT-KO and DAT/SERT double-KO mouse littermates from crosses of heterozygous DAT/homozygous SERT knockout mice on a 129/C57 mixed genetic background also served as subjects.
The experimental procedures and housing conditions were approved by the Institutional Animal Care and Use Committee of Tokyo Institute of Psychiatry, and all animals were cared for and treated humanely in accordance with our institutional animal experimentation guidelines. Naive adult mice were housed in an animal facility maintained at 22 ± 2°C and 55 ± 5% relative humidity under a 12 h light/dark cycle with lights on at 8:00 a.m. and off at 8:00 p.m. Food and water were available ad libitum. In microdialysis experiments, male and female mice from 10 to 24 weeks old were examined.

Surgery and Microdialysis Procedure

Mice were stereotaxically implanted, under sodium pentobarbital anesthesia (50 mg/kg, intraperitoneally), with microdialysis probes in the striatum (anterior +0.6 mm, lateral +1.8 mm, ventral -4.0 mm from bregma) or PFC (anterior +2.0 mm, lateral -0.5 mm, ventral -3.0 mm from bregma), according to the atlas of Franklin and Paxinos [24]. Twenty-four hours after implantation, the dialysis experiments were performed in freely-moving animals. Evaluation of DAex and 5-HTex has been previously described [25]. Basal levels of DAex and 5-HTex were obtained from average concentrations of three consecutive samples when they were stable.

Statistical Analysis

AUC values of all groups were analyzed using a two-way analysis of variance (ANOVA). Individual post hoc comparisons were performed with Fisher’s protected least significant difference (PLSD) test. When the effects of MDMA were analyzed posttreatment period revealed significant effects of drug ($F_{2,25} = 94.751, p < 0.001$) and genotype ($F_{1,25} = 26.775, p < 0.001$) and a significant drug × genotype interaction ($F_{2,25} = 21.352, p < 0.001$). Post hoc comparisons revealed that the effects of MDMA (10 mg/kg) on DAex in SERT-KO mice was significantly less than in wildtype mice ($p < 0.001$; Fisher’s PLSD post hoc test). However, DAT-KO mice exhibited significant MDMA (10 mg/kg)-induced increases in DAex levels ($p < 0.001$; Fisher’s PLSD post hoc test), increases that were less than in wildtype mice ($p < 0.001$; Fisher’s PLSD post hoc test). MDMA (3 and 10 mg/kg) dose-dependently increased 5-HTex in wildtype and DAT-KO mice (Fig. 1A, B). Two-way ANOVA (drug × genotype) of DAex AUC calculated during the 180 min posttreatment period revealed significant effects of drug ($F_{2,25} = 23.578, p < 0.001$) and genotype ($F_{3,25} = 21.589, p < 0.001$) and a significant drug × genotype interaction ($F_{6,58} = 7.769, p < 0.001$). The effects of MDMA (3 and 10 mg/kg) on 5-HTex in DAT-KO mice was significantly higher than in wildtype mice ($p < 0.05$ and $p < 0.01$, respectively; Fisher’s PLSD post hoc test). When the effects of MDMA were analyzed only in SERT-KO and DAT/SERT double-KO mice, two-way ANOVA (drug × genotype) of 5-HTex revealed a significant effect of drug ($F_{2,25} = 11.858, p < 0.001$) but no effect of genotype ($F_{1,25} = 0.492, p = 0.489$) and no drug × genotype interaction ($F_{2,25} = 2.773, p = 0.082$). The effects of

| Genotype           | n   | DAex       | 5-HTex     | n   | DAex       | 5-HTex     |
|--------------------|-----|------------|------------|-----|------------|------------|
| Wildtype           | 20  | 43.00 ± 5.15 | 1.24 ± 0.17 | 24  | 1.24 ± 0.18 | 1.87 ± 0.20 |
| DAT-KO             | 19  | 486.26 ± 62.00*** | 1.01 ± 0.13 | 21  | 1.16 ± 0.16 | 1.87 ± 0.24 |
| SERT-KO            | 16  | 56.18 ± 7.44  | 13.07 ± 1.97*** | 16  | 1.32 ± 0.28 | 15.09 ± 1.73*** |
| DAT/SERT-KO        | 15  | 596.18 ± 73.38*** | 15.13 ± 1.91*** | 19  | 1.42 ± 0.22 | 12.21 ± 1.43*** |

Data presented are means ± S.E.M. ***P < 0.001 compared to the corresponding wildtype datum.
Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice

Current Neuropharmacology, 2011, Vol. 9, No. 1

93

Effects of MDMA on DA_{ex} and 5-HT_{ex} in the PFC

MDMA (3 and 10 mg/kg) dose-dependently increased DA_{ex} in wildtype, DAT-KO, SERT-KO, and DAT/SERT double-KO mice (Fig. 2A, B). Two-way ANOVA (drug × genotype) of DA_{ex} revealed significant effects of drug ($F_{2,68} = 53.368, p < 0.001$) but no effect of genotype ($F_{3,68} = 0.203, p = 0.894$) and no drug × genotype interaction ($F_{6,68} = 0.408, p = 0.871$). MDMA (3 and 10 mg/kg) dose-dependently increased 5-HT_{ex} in wildtype and DAT-KO mice (Fig. 2C, D). Two-way ANOVA (drug × genotype) of 5-HT_{ex} revealed significant effects of drug ($F_{2,68} = 32.357, p < 0.001$) and genotype ($F_{3,68} = 19.078, p < 0.001$) and a significant drug × genotype interaction ($F_{6,68} = 10.596, p < 0.001$). The effect of MDMA (10 mg/kg) on 5-HT_{ex} in DAT-KO mice was significantly less than in wildtype mice (p < 0.01; Fisher’s PLSD post hoc test). When the effects of MDMA were analyzed only in SERT-KO and DAT/SERT double-KO mice, two-way ANOVA (drug × genotype) of 5-HT_{ex} revealed a significant effect of drug ($F_{2,29} = 28.906, p < 0.001$) but no significant effect of genotype ($F_{1,29} = 0.236, p = 0.631$) and no drug × genotype interaction ($F_{2,29} = 0.609, p = 0.551$).

Fig. (1). Effects of MDMA on DA_{ex} and 5-HT_{ex} in the striatum in wildtype, DAT-KO, SERT-KO, and DAT/SERT double-KO mice. (A, C) Temporal pattern of DA_{ex} and 5-HT_{ex} before and after injection with saline or MDMA (3 and 10 mg/kg, s.c.). The arrows indicate drug injection time. Each point represents the mean ± SEM of the percentage of DA_{ex} or 5-HT_{ex} baselines. (B, D) Histogram representing the mean AUC (± SEM) of DA_{ex} or 5-HT_{ex} during the 180 min period after injection with saline or MDMA ($n = 4-8$). *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, compared with saline group of the same genotype; $#p < 0.05$, ##$p < 0.01$, ###$p < 0.001$, compared with corresponding wildtype data in the same drug treatment (two-way ANOVA followed by Fisher’s PLSD post hoc test).

DISCUSSION

MDMA increased DA_{ex} and 5-HT_{ex} in the striatum and PFC, consistent with several previous microdialysis studies [7, 10-13]. In DAT/SERT double-KO mice, MDMA did not increase DA_{ex} in the striatum, and the increases in 5-HT_{ex} were minimal in the striatum and PFC. These results confirm that MDMA acts at both the DAT and SERT.

MDMA increased DA_{ex} in wildtype and SERT-KO mice, but not in DAT/SERT double-KO mice. In the absence of the DAT, MDMA-induced changes in DA_{ex} were smaller than in wildtype mice. Therefore, the DAT is likely mainly involved in the changes in DA_{ex} induced by MDMA. Although DAT-KO mice exhibited significant MDMA-induced increases in DA_{ex} levels, these increases were less than in wildtype mice. The increase in DA_{ex} produced by MDMA in DAT-KO mice may have two possible explanations. One possibility is that elevated 5-HT_{ex} levels produced by MDMA may influence DA release. Microdialysis studies have shown that MDMA, by increasing 5-HT_{ex} indirectly increases DA_{ex} via an action at 5-HT_2 receptors [7, 8, 17]. Another possibility is that MDMA inhibits DA uptake into 5-HT axon terminals and increases DA_{ex}. The SERT is able to transport DA into 5-HT cells [26, 27], and the selective SERT blocker fluoxetine increases DA_{ex} in the striatum of DAT-KO mice [25].
Microdialysis studies have shown that NET inhibitors increased DA_{ex} in the PFC [28, 29], suggesting that NET can influence DA neurotransmission. Moron et al. (2002) reported that DA uptake in the PFC depends primarily on the NET [30]. This study showed a similar basal extracellular DA concentration in the PFC in DAT-KO and wildtype mice. DA_{ex} in the PFC is regulated by the NET. MDMA dose-dependently increased DA_{ex} in wildtype, DAT-KO, SERT-KO, and DAT/SERT double-KO mice. Therefore, MDMA may act at the NET and increase DA_{ex} levels in the PFC.

MDMA slightly increased 5-HT_{ex} in the striatum and PFC in mice lacking the SERT. The selective DAT blocker GBR12909 produced a substantial increase in dialysate 5-HT in SERT-KO mice that was not found in wildtype mice [25]. When the SERT is disrupted in SERT-KO mice, 5-HT is found in DA neurons in the substantia nigra and ventral tegmental area [31]. The DAT appears to play a compensatory role in 5-HT uptake in SERT-KO mice. Therefore, MDMA may act at the DAT and increase 5-HT_{ex} levels in the striatum in SERT-KO mice. The NET also appears to be able to play a role in 5-HT uptake [32]. In the PFC, MDMA may increase 5-HT_{ex} levels by acting at the NET in SERT-KO mice.

MDMA markedly increased 5-HT_{ex} in wildtype and DAT-KO mice. MDMA binds with higher affinity to the SERT than to the DAT [5, 6]. Consistent with in vitro results, MDMA produced greater elevations in 5-HT than DA. Relevant studies have shown that many of the subjective effects of MDMA in human volunteers are reduced after administration of a 5-HT_{2} receptor antagonist or 5-HT reuptake inhibitors, suggesting that these effects are dependent on SERT-mediated enhancement of serotonergic transmission [33, 34].

In conclusion, the present microdialysis study using DAT- and/or SERT-KO mice demonstrated that MDMA targets monoamine transporters and stimulates predominantly serotonergic transmission.

ACKNOWLEDGEMENTS

We acknowledge Mr. Michael Arends for his assistance with editing the manuscript and Ms. Junko Hasegawa for her assistance with genotyping mice. This work was supported by a research grant (17025054) from the MEXT of Japan, by grants from the MHLW of Japan (H17-pharmaco-001, H19-iyaku-023, and 18A-3 and 19A-8 for Nervous and Mental Disorders), by a grant from the Smoking Research Founda-
Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice

REFERENCES

1. Johnson, M.P.; Conarty, P.F.; Nichols, D.E. [1H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. *Eur. J. Pharmacol.*, 1991, 200, 9-16.

2. Fitzgerald, J.L.; Reid, J.J. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. *Eur. J. Pharmacol.*, 1990, 191, 217-220.

3. Johnson, M.P.; Hoffman, A.J.; Nichols, D.E. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. *Eur. J. Pharmacol.*, 1986, 132, 269-276.

4. Schmidt, C.J.; Levin, J.A.; Lovenberg, W. *In vitro and in vivo* neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. *Biochem. Pharmacol.*, 1987, 36, 747-755.

5. Rothman, R.B.; Baumann, M.H. Monoamine transporters and psychostimulant drugs. *Eur. J. Pharmacol.*, 2003, 479, 23-40.

6. Han, D.D.; Gu, H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. *BMC Pharmacol.*, 2006, 6, 6.

7. Gudelsky, G.A.; Yamamoto, B.K.; Nash, J.F. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. *Eur. J. Pharmacol.*, 1994, 264, 325-330.

8. Yamamoto, B.K.; Nash, J.F.; Gudelsky, G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. *J. Pharmacol. Exp. Ther.*, 1995, 273, 1063-1070.

9. Koch, S.; Galloway, M.P. MDMA induced dopamine release in *vivo*: role of endogenous serotonin. *J. Neural Transm.*, 1997, 104, 135-146.

10. Baumann, M.H.; Clark, R.D.; Rothman, R.B. Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. *Pharmacol. Biochem. Behav.*, 2008, 90, 208-217.

11. Gudelsky, G.A.; Nash, J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. *J. Neurochem.*, 1996, 66, 243-249.

12. Nair, S.G.; Gudelsky, G.A. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat brain. *Brain Res.*, 2004, 1013, 168-173.

13. Trigo, J.M.; Renoir, T.; Lanfumey, L.; Hamon, M.; Lesch, K.P.; Roques, B.P. MDMA-induced self-administration is abolished in serotonin transporter knockout mice. *Biol. Psychiatry*, 2007, 62, 669-679.

14. Nash, J.F.; Brodkin, J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. *J. Pharmacol. Exp. Ther.*, 1991, 259, 820-825.

15. Shankaran, M.; Yamamoto, B.K.; Gudelsky, G.A. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxy radicals and long-term depletion of serotonin in the striatum. *J. Neurochem.*, 1999, 72, 2516-2522.

16. Nash, J.F. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by *in vivo* microdialysis. *Life Sci.*, 1990, 47, 2401-2408.

17. Schmidt, C.J.; Sullivan, C.K.; Fadayel, G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. *J. Neurochem.*, 1994, 62, 1382-1389.

18. Bengel, D.; Murphy, D.L.; Andrews, A.M.; Wichems, C.H.; Feltner, D.; Heils, A.; Mossner, R.; Westphal, H.; Lesch, K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. *Mol. Pharmacol.*, 1998, 53, 649-655.

19. Peng, W.; Simantov, R. Altered gene expression in frontal cortex and midbrain of 3,4-methylenedioxymethamphetamine (MDMA) treated mice: differential regulation of GABA transporter subtypes. *J. Neurosci.*, 2003, 72, 250-258.

20. Giros, B.; Jaber, M.; Jones, S.R.; Wightman, R.M.; Caron, M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature*, 1996, 379, 606-612.

21. Sora, I.; Wichems, C.; Takahashi, N.; Li, X.F.; Zeng, Z.; Revay, R.; Lesch, K.P.; Murphy, D.L.; Uhl, G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and serotonin-transporter knockout mice. *Proc. Natl. Acad. Sci. USA*, 1998, 95, 7669-7704.

22. Ralph, R.J.; Paulus, M.P.; Fumagalli, F.; Caron, M.G.; Geyer, M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knockout mice: differential effects of D1 and D2 receptor antagonists. *J. Neurosci.*, 2001, 21, 305-313.

23. Powell, S.B.; Lehmann-Masten, V.D.; Paulus, M.P.; Gainetdinov, R.R.; Caron, M.G.; Geyer, M.A. MDMA "Ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. *Psychopharmacology (Berl)*, 2004, 173, 310-317.

24. Franklin, K.B.J., Paxinos, G. The mouse brain in stereotaxic coordinates. Academic Press: San Diego, 1997.

25. Shen, H.W.; Hagiya, H.; Kobayashi, H.; Shinohara-Tanaka, K.; Ikeda, K.; Yamamoto, H.; Yamamoto, T.; Lesch, K.P.; Murphy, D.L.; Hall, F.S.; Uhl, G.R.; Sora, I. Regional differences in extracellular dopamine and serotonin assessed by *in vivo* microdialysis in mice lacking dopamine and/or serotonin transporters. *Neuropsychopharmacology*, 2004, 29, 1790-1799.

26. Schmidt, C.J.; Lovenberg, W. *In vitro* demonstration of dopamine uptake by neostriatal serotoninergic neurons of the rat. *Neurosci. Lett.*, 1985, 59, 9-14.

27. Faraj, B.A.; Olikowski, Z.L.; Jackson, R.T. Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. *Pharmacology*, 1994, 48, 320-327.

28. Carboni, E.; Tanda, G.L.; Frau, R.; Di Chiara, G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in *vivo* by noradrenergic terminals. *J. Neurochem.*, 1990, 55, 1067-1070.

29. Yamamoto, B.K.; Novotney, S. Regulation of extracellular dopamine by the norepinephrine transporter. *J. Neurochem.*, 1998, 71, 274-280.

30. Moron, J.A.; Brockington, A.; Wise, R.A.; Rocha, B.A.; Hope, R.D. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. *J. Neurosci.*, 2002, 22, 389-395.

31. Zhou, F.C.; Lesch, K.P.; Murphy, D.L. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. *Brain Res.*, 2002, 942, 109-119.

32. Daws, L.C.; Montanez, S.; Owens, W.A.; Gould, G.G.; Frazer, A.; Toney, G.M.; Gerhardt, G.A. Transport mechanisms governing serotonin clearance in *vivo* revealed by high-speed chronopamperometry. *J. Neurosci. Methods*, 2005, 143, 49-62.

33. Liechti, M.E.; Baumann, C.; Gamma, A.; Vollenweider, F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitors citalopram and fluoxetine. *Neuropsychopharmacology*, 2000, 22, 513-521.

34. Liechti, M.E.; Saur, M.R.; Gamma, A.; Hell, D.; Vollenweider, F.X. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. *Neuropsychopharmacology*, 2000, 23, 396-404.